Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Neoplasms 5Stomach Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Advanced Solid Tumors 4Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thoracic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Lung Cancer 1

Interventions

Gemcitabine 13Oxaliplatin 9Capecitabine 6lenvatinib 5apatinib 5Cisplatin 5tislelizumab 4Surgical Procedures, Operative 4Radiofrequency Ablation 4Neoadjuvant Therapy 4Fluorouracil 4toripalimab 3sintilimab 3Radiotherapy 3Leucovorin 3Irinotecan 3regorafenib 2pembrolizumab 2durvalumab 2camrelizumab 2Stents 2Photochemotherapy 2Immunotherapy 2Hepatectomy 2Folfox protocol 2Everolimus 2Drug Therapy 2Cholangiopancreatography, Endoscopic Retrograde 2Blood Specimen Collection 21-phenyl-3,3-dimethyltriazene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Cholangiocarcinoma × Injections × Clear all
NCT04454905 2023-04-19

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡